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ABSTRACT
Deubiquitinases (DUBs) are crucial determinants of protein stability, 
localization, complex formation and activity within cells (1). The OTUD6B 
DUB has been previously linked to cell growth and proliferation (2). More 
specifically, the isoform OTUD6B-2 may promote protein synthesis and DNA 
synthesis through deubiquitination of c-Myc (2). We established 
OTUD6B-knockout A549 and H1299 non-small cell lung cancer (NSCLC) cell 
lines to determine how OTUD6B contributes to the malignant potential of 
cancer. To delete OTUD6B expression, we utilized clustered regularly 
interspaced short palindromic repeats (CRISPR) technology, using short RNA 
guides to direct an endonuclease (Cas9) to specific sites on genomic DNA 
(3). Our approach involved double nicking/homologous recombination 
insertion (4) of an antibiotic resistance cassette into the OTUD6B exon IV.
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INTRODUCTION
● Lung cancer is one of the most frequently diagnosed forms of cancer, making up approximately 11.6% of total cases 
worldwide (7).
● It is also the leading cause of cancer-related deaths in both women and men, comprising about 18.4% of total cancer 
deaths (7).
● Despite treatment, only 15.9% of patients with the disease are alive within five years of diagnosis (all stages; 8).
● Approximately 85% of all new lung cancer diagnoses are non-small-cell lung cancer (NSCLC) (9).
● Because of the asymptomatic nature of the early stages of NSCLC, this malignancy is predominantly diagnosed at 
advanced stages. Since early diagnostic technology remains problematic, NSCLC is still usually treated using 
non-targeted drugs such as platin and taxanes (10).
● Although initially effective, cancer cells rapidly develops resistance to these drugs during treatment (10). 
● Thus, it is crucial that new specific therapeutic targets to treat NSCLC are identified.
● This study examined the effects of this insertion guided by homologous recombination in NSCLC cells in order to see if it 
successfully inhibits the growth phenotype of these cells.
METHODOLOGY
● Tissue culturing using A549 and H1299 ACL cell lines (American Type Culture Collection ) and cells were transfected by electroporation.
● Viable cells were counted in a hemocytometer using trypan blue exclusion dye techniques.
● PCR amplification was performed using restriction sites KpnI and NotI.
● The amplified DNA underwent digestions. 
● Gel purification, ligation, and agar plates were then prepared.
● The DNA was then isolated using maxi and mini preparations, and immunoblotting was performed.
CONCLUSIONS
● OTUD6B gene ablation in ACL cell lines is feasible using the CRISPR/Cas9 system.
○ Appears to lead to complete growth arrest of NSCLC cells
● Our data seems to confirm that OTUD6B is essential for NSCLC cell proliferation in the cell lines we have tested.
● Future studies within this project will help us improve our understanding of the contribution of OTUD6B to c-Myc stability through reintroduction of the gene into OTUD6B-knockout cells with a 
controllable promoter.
○ This will allow us to confirm our results by testing to see if reintroduction of OTUD6B reverses growth arrest
● The results of this project provide valuable information that improves our understanding of protein synthesis in NSCLC.
● We hope our data can contribute to the development of new lung cancer treatments and therapies in a clinical research setting.
CRISPR knockout of the DUB OTUD6B 
in lung cancer cells
Miriam Franks1, Suhitha Irukulla1,  Nayonika Roy1,  and Dr. Maurizio 
Bocchetta2 
1 2
Shows the pMF410 plasmid vector (27). This vector contains the gene for 
Cas9 D10a (red), an endonuclease that induces double-stranded nicking of 
the host cell genome. It also codes for two U6 promoters (blue), which 
increase transcription of the two crRNA genes (green) and the two tracrRNA 
genes (purple) These genes code for the RNA strands that guide the Cas9 
enzyme to the correct part of the cell’s DNA. Specifically, crRNAs contain 
spacers, while tracrRNAs are the scaffolds of the sgRNAs.
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Depicts the nucleotide sequence of OTUD6B. Figure A shows the left (yellow) and right (blue) regions of recombination. 
The green highlighted nucleotides indicate the overlap between the two regions. Figure B shows the locations of the 
PAM sequences (red) and the regions homologous to the sgRNAs.
Shows photographs of AdenoCarcinoma of the Lung (ACL) cells 
from the H1299 cell line before and after transfection and two 
months of neomycin-resistance (G148) selection. The H1299 
cells before transfection (left) display a small, round phenotype 
and are not contact-inhibited (i.e., they tend to grow on top of 
each other) compared to those depicted in the image of H1299 
cells post-transfection and selection (right). The cells on the 
right also display an elongated, enlarged phenotype and 
appear contact-inhibited.
1. Sahtoe DD, Sixma TK. Layers of DUB regulation. Trends Biochem Sci 2015;40:456-67.  
2. Sobol A, Askonas C, Alani S, Weber MJ, Ananthanarayanan V, Osipo C, Bocchetta M. Deubiquitinase OTUD6B Isoforms Are Important Regulators of 
Growth and Proliferation. Mol Cancer Res. 2017; 15(2):117–27.
3. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 
(2013).
4. https://www.addgene.org/crispr/guide/.
5. Chiang, T.-W. W., le Sage, C., Delphine, L., Mukerrem, D. & Jackson, S. P. CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to 
enhance genome editing. Sci. Rep. 6, 24356 (2016).
6. Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kühn R. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced 
precise gene editing in mammalian cells. Nat Biotechnol 2015;33:543-8.
7.  Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality 
worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; doi: 10.3322/caac.21492.
8. Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015. doi: 10.1038/nrdp.2015.9.
9. Ettinger DS, Akerley W, Bepler G, et al: Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801, 2010
10. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq.
11. Tanaka K. (2009). The proteasome: overview of structure and functions. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 85, 12–36. 10.2183/pjab.85.12.
12. Kulathu, Y. et al. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nature Commun. 4, 1569 (2013).
13. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014;4:a014241.
14. Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y. Inhibition of Myc effectively 
targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res 2010;30:4193-200.
15. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 
2011;25:907-16.




20. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Second edition. Nola C Ed. Cold Spring Harbor Laboratory Press. 1989.
21. https://www.addgene.org/protocols/inoculate-bacterial-culture/.
22. Trevino AE, Zhang F. Genome editing using Cas9 nickases. Methods Enzymol 2014;546:161-74.
23. Dianov GL, Hübscher U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res 2013;41:3483-90.





29. Berens C, Altschmied L, Hillen W. The role of the N terminus in Tet repressor for tet operator binding determined by a mutational analysis. J Biol Chem 
1992;267:1945-52.
